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Oxidants have long been recognized to have an important role in the pathogenesis of COPD, and in this cigarette
smoke has a strong responsibility, because it generates a conspicuous amount of oxidant radicals able to modify
the structure of the respiratory tract and to enhance several mechanisms that sustain lung inflammation in COPD.
In fact, oxidative stress is highly increased in COPD and natural antioxidant capacities, mainly afforded by reduced
glutathione, are often overcome. Thus an exogenous supplementation of antioxidant compounds is mandatory to
at least partially counteract the oxidative stress. For this purpose N-acetylcysteine has great potentialities due to its
capacity of directly contrasting oxidants with its free thiols, and to the possibility it has of acting as donor of
cysteine precursors aimed at glutathione restoration. Many studies in vitro and in vivo have already demonstrated
the antioxidant capacity of NAC. Many clinical studies have long been performed to explore the efficacy of NAC in
COPD with altern results, especially when the drug was used at very low dosage and/or for a short period of time.
More recently, several trials have been conducted to verify the appropriateness of using high-dose NAC in COPD,
above all to decrease the exacerbations rate. The results have been encouraging, even if some of the data come
from the most widely sized trials that have been conducted in Chinese populations. Although other evidence
should be necessary to confirm the results in other populations of patients, high-dose oral NAC nevertheless offers
interesting perspectives as add-on therapy for COPD patients.
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Background
Chronic Obstructive Pulmonary Disease (COPD), a
common, preventable and treatable disease, is character-
ized by a chronic airflow obstruction that is usually
progressive and scarcely reversible,caused by a variable
association of chronic bronchitis, small airways damage
and pulmonary emphysema, consequent to inhalation of
noxious particles and gases, especially tobacco smoke,
inducing a chronic airway inflammation, and frequently
associated with several comorbidities [1, 2].
The characteristic pathological changes in the lungs of
COPD patients are sustained by an inflammation where
a pivotal role is exerted by excessive oxidant stress and
protease imbalance [3, 4].
A wide variety of oxidants, free radicals and others
agents are implicated in the pathogenesis of COPD, thus
the administration of antioxidants seems a rational ad-
junct to the treatment of the disease and in this respect
the oral administration of N-acetylcysteine (NAC)
proved effective in decreasing oxidative biomarkers in
peripheral blood and exhaled breath condensate, and in
reducing the rate of COPD exacerbations [5–9].
Role of oxidative stress in COPD pathogenesis
COPD is a chronic disease, presenting with different
phenotypes and frequent exacerbation episodes, based
on a pulmonary and extrapulmonary inflammation with
increase also in reactive oxygen species (ROS). Oxidants
have long been recognized to have an important role in
the pathogenesis of COPD [3, 4, 10–12], because,
besides a direct lung damage, they also enable the activa-
tion of transcription factors like nuclear factor NF-kB
with consequent production of inflammatory proteins
and damage of antiproteases [13].
Oxidant compounds are highly reactive oxygen radi-
cals, originated from the reduction of molecular oxygen
in the course of physiological and pathological processes,
able to induce a chemical reaction (redox cycle) where
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the oxidant takes up electrons from another compound
and then transfers them to other molecules so inducing
structural and functional alterations. In biological pro-
cesses the true radicals mainly involved are superoxide,
hydroxyl, hydroperoxyl, nitrogen dioxide, while non rad-
icals compounds like singlet oxygen, ozone, and hydro-
gen peroxide can also be important by generating other
radicals [3].
Oxygen free radicals, having various and different cel-
lular penetration and activity [14], can substantially
recognize exogenous and endogenous origin. Air pollut-
ants, both gaseous and particulate matter, are a major
exogenous source of oxidants through the formation of
ROS that, overwhelming antioxidant defences, can react
with DNA, lipids and proteins, so inducing short-term
and long-term effects by activating signaling pathways,
enhancing inflammatory and degenerative processes,
and impairing the protective mechanisms [15]. Oxi-
dants may also derive from the redox cycle of drugs
or toxins, and in case of exposition to hyperoxia.
Agents like bleomycin, alloxan, doxorubicin, paraceta-
mol and others are able to generate superoxide an-
ions and hydroxyl radicals [3].
Among the exogenous sources of oxidants, cigarette
smoke has a prominent position because it contains a
very high amount of radicals per puff [16] and it can also
activate inflammatory cells to deliver ROS. In fact, the
oxidant load in the respiratory tract is further aug-
mented due to the increased amount of inflammatory
cells at this site, and a close correlation has been demon-
strated by cigarette smoking and neutrophils production,
increased circulation, and sequestration in lung capillar-
ies [17]. After sequestration, neutrophils are chemotacti-
cally attracted to the airways and lung parenchyma
where they can deliver powerful oxidants and proteases
[18]. Macrophages are also activated by cigarette smoke
to release inflammatory mediators and ROS [19]. Thus,
cigarette smoking, a very frequent habit in COPD pa-
tients, has to be considered the main contributing factor
to oxidative stress in these patients. Other than exerting
a direct injury to the lungs, oxidant radicals can also
stimulate or exacerbate other important mechanisms
like inflammation, protease/antiprotease imbalance and
apoptosis [3, 20–23].
Physiological processes in the body are an endogenous
source of free radicals with the complete reduction of an
oxygen molecule to water. It is critical for cellular respir-
ation, because the mitochondrial electron transport
chain originates hydrogen peroxide. The toxic com-
pounds so generated are usually completely balanced by
the antioxidant defenses. Apart from these physiological
processes, a strong endogenous source of ROS in the
lungs is represented by inflammatory cells, like neutro-
phils and eosinophils, and by macrophages, epithelial
and endothelial cells, all of which can also be activated by
the inhalation of exogenous pollutants, like particulate
matter, sulphur dioxide and nitrous dioxide, to produce
ROS, mainly superoxide anions and hydrogen peroxide
[24, 25]. Some transcriptional factors implicated in inflam-
matory processes, like NF-kB and activator protein-1 (AP-
1) are activated by oxidative stimuli and mediate the ex-
pression of cytokine and other biological agents [26, 27].
The term “oxidative stress”, clearly demonstrated in
smokers and in COPD patients [20, 28], specifically
means an imbalance between the burden of oxidants in
the lung and the amount of antioxidants in favor of the
former, mainly caused by cigarette smoking and poten-
tially able to endanger the lung structure and function.
Following the exposure to toxins and cigarette smoke,
alveolar epithelium releases chemotactic agents for
inflammatory cells recruitment and consequent lung
damage [29]. The lung matrix (elastin, collagen) and the
alveolar epithelial surface directly exposed to inhaled
pollutants can be damaged especially when the protect-
ive activity of intra- and extracellular glutathione is over-
whelmed by oxidant burden [30].
The attack of oxidants to fatty acids of cellular
membranes triggers the process of lipid peroxidation
with generation of hydroperoxides and other unstable
compounds that can amplify the reaction. Such com-
pounds are increased in smokers and in COPD patients
[7, 10, 31, 32] and testify close interrelationships between
markers of inflammation and oxidative mechanisms in the
pathogenesis of COPD [33–35].
Furthermore, a positive correlation has been dem-
onstrated between the value of forced expiratory vol-
ume in one second (FEV1) and antioxidant level in
plasma [36, 37], whereas antioxidant depletion was
more frequent in severe COPD patients with frequent
exacerbations [38].
Endogenous and exogenous antioxidant defenses
Antioxidant protection in the tissues and also in the re-
spiratory tract is mainly provided by the glutathione
(GSH), a redox-cycler thiol present in epithelial lining
fluid, that, by transforming from the reduced to oxidized
form, exerts a powerful antioxidant effect and then is
converted again to the reduced form by the enzyme
glutathione reductase. The antioxidant action of gluta-
thione associates also with some enzymatic activities,
like aldehyde dehydrogenase and superoxide dismutase,
able to counteract the oxidant and inflammatory reac-
tions of cigarette smoke [37, 39]. Among the endogen-
ous defenses a distinct role has also the transcription
factor nuclear erythroid-related factor 2 (Nrf2) that, in
presence of excessive oxidant burden, translocates from
the cytoplasm to the nucleus enhancing the production
of antioxidant genes [40–42].
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All these endogenous antioxidant mechanisms can
be overcome in COPD patients, mainly in strong
smokers or ex-smokers, by an increased oxidative
stress [3, 10, 28]. As a matter of fact, GSH content in
alveolar cells was shown to be reduced following
acute exposure to cigarette smoke in animal experi-
ments [43] and its levels were also reduced in COPD
patients due to a downregulation of glutathione bio-
synthetic enzymes [42] whose content indirectly cor-
relates with the severity of the respiratory disease
[41]. The oxidative stress can also reduce the activity
of the enzyme histone deacetylase-2, thus enhancing
the transcription of proinflammatory genes and indu-
cing a corticosteroid resistance [44, 45]. COPD exac-
erbations further aggravate this situation as demonstrated
by the decreased level of GSH in bronchoalveolar lav-
age fluid during acute episodes compared to stable
state [46, 47].
As to the exogenous antioxidant supply, the results of
many investigations are not always concordant. Epi-
demiological studies carried out many years ago in gen-
eral population showed a small but significant increase
in respiratory function correlated with a dietary intake of
vitamin C and less likely of vitamin E [48]. These results
were confirmed some years later in a wide Dutch study,
where the intake of vitamin C and beta-carotene was as-
sociated with better respiratory function values [49].
However, the supplementation of vitamin antioxidants
did not result in improved symptoms or respiratory
function in almost thirty thousand COPD patients [50],
whereas in another study a protective role for vitamin C
against the risk of obstructive airways disease has
been demonstrated, probably due to the counteracting
action of this vitamin on the effects of cigarette
smoking [51]. Even a high intake of catechins, a sub-
class of antioxidant flavonoids, and of solid fruits was
proven to exert a beneficial effect against COPD [52].
Resveratrol is a polyphenol synthesized by some vege-
tal species that displays various biological activities
among which anti-inflammatory and antioxidant prop-
erties [53–55].
However, the reduced glutathione system is the main-
stay of the defenses against oxidative stress and in case
of excessive consumption of GSH its restoration cannot
be provided only by dietary supply, and exogenous sup-
plementation with thiol groups donors or compounds
enhancing the GSH synthesis may be necessary. In this
respect N-acetylcysteine (NAC), a substance whose effi-
cacy has been in the past almost exclusively attributed to
its mucolytic properties [56, 57], has eventually been
demonstrated able to counteract oxidant burden both
directly by its thiolic free groups acting in the extracellu-
lar environment [58], and indirectly by providing intra-
cellularly cysteine for GSH synthesis [59].
The basis for N-acetylcysteine as an antioxidant
and anti-inflammatory agent
The protection afforded by NAC against oxidants has
been recognized many decades ago, even if its bioavail-
ability when administered orally was not fully described
and the main useful effect of the drug was more recently
recognized as precursor of GSH [60]. N-acetylcysteine
when administered orally is deacetylated to cysteine,
with consequent increase in the concentration of re-
duced glutathione in plasma and airways, as demon-
strated by the increase of GSH in bonchoalveolar lavage
fluid after administration of NAC, and by the active up-
take of glutathione from plasma by the lungs, that are
the main place of GSH synthesis together with the liver
[61, 62]. A study performed some years later was able to
confirm the increase of GSH in plasma of COPD pa-
tients, while it was not increased in bronchoalveolar lav-
age fluid, after high daily doses of NAC when
administered for a short period of time, in this case for
five days only [63].
However, a protection of the alveolar epithelium from
oxygen toxicity by NAC was shown long time ago both
in vitro and in vivo in animal experiments [64, 65]. The
free thiol group of NAC can interact with electrophilic
residual of reactive oxygen species with subsequent for-
mation of intermediate compounds like NAC disulphide
[59, 60, 66, 67]. Direct administration of L-cysteine is
impaired by its low intestinal absorption and rapid me-
tabolism in the liver, while NAC, rapidly absorbed after
oral administration, allows to overcome these disadvan-
tages [67–69] and to restore the intracellular GSH de-
creased by the oxidative stress and inflammatory
processes [70–72]. Exogenous NAC was able to restore
intracellular content of thiols, whereas GSH
administration was not [69, 73]. Only a limited plasma
increase in GSH was recorded in healthy subjects given
600 mg NAC [74], demonstrating a clear use of NAC
per os.
Some studies have demonstrated a dose-dependent
effect of NAC in COPD patients, because the usual dose
of 600 mg once daily was not able to increase GSH,
while it occurred when NAC was administered three
times a day [63]. Owing to its antioxidant properties,
NAC is able to maintain the redox-dependent cell-
signaling and transcription, in particular the Nuclear
Factor–kB (NF-kB), p38 MAPK and others, critical for
proinflammatory genes regulation [75, 76]. This
favourable effect of NAC may be induced by low NAC
doses if the administration period is sufficiently pro-
longed, but it can be more rapidly achieved with higher
NAC daily doses chronically given, that likely exert a
more marked control on the activation of inflammatory
factor like NF-kb [69], demonstrating a useful use of
high dose of NAC per os.
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More recently, a new mechanism of NAC action has
been demonstrated in animals exposed to cigarette
smoke, concerning the positive effect of NAC on nuclear
erythroid 2–related factor–2 (Nrf2) transcription factor
that has a crucial role as regulator of cellular redox
status [77] also in COPD patients where it has been
shown to be decreased [41, 78].
Clinical studies of NAC administration in COPD
patients
There are in the literature many studies that found
beneficial effect of NAC in humans in terms of preserv-
ing oxidant/antioxidant homeostasis through the in-
crease in GSH, the decrease in the content and
activation of inflammatory cells in sputum and in BAL
[33, 61, 79–81] but also, many trials that investigated the
effect of oral administration of NAC on the ROS produc-
tion as evidenced in exhaled breath condensate (EBC).
About twenty years ago Dekhuijzen [10] first re-
vealed an increased content of oxidants (hydrogen
peroxide,H2O2) in EBC of clinically stable COPD pa-
tients compared to healthy subjects, and the H2O2
level was even significantly higher in exacerbated
COPD patients than in the stable ones. The same results
were obtained by Novak et al. [82]. Subsequently, De
Benedetto et al. [83], using a new technique allowing to
minimize the inaccuracy deriving from the instability of
hydrogen peroxide, assessed the level of this compound
in EBC of normal subjects and of stable patients with
mild to moderate COPD, confirming that mean H2O2
level in exhaled air of COPD patients (0.50 ± 0.11SD μM)
was significantly (p = 0.0001) increased compared to that
in healthy subjects (0.12 ± 0.09 μM). Thus, even in a stable
clinical condition, COPD is sustained by chronic inflam-
matory processes also involving oxidant production, and
this production is even more increased during exacerba-
tion episodes [10].
Several trials in the past investigated the usefulness of
oral administration of NAC, generally 600 mg/day in
chronic bronchitis and COPD patients above all to pre-
vent exacerbations [8, 84–86], obtaining positive results
[8], even if some studies only observed a positive clinical
trend without statistical correspondence [86].
At the beginning of the present century Stey et al. [9]
performed a systematic review of 11 studies published
until 1994, where NAC had been compared to placebo
in over 2 thousand COPD patients, and the results were
in favor of NAC, whose administration for 12 to
24 months decreased the rate of exacerbations and the
symptoms score, irrespective of duration of therapy or
of cumulative dose administered. The same year, another
meta-analysis [87] conducted on 8 studies qualified for
inclusion published until 1995, with NAC administered
orally at a maximal dose of 600 mg/day in six studies, at
1200 mg/day in one study, and at 1800 mg/day in another
one, confirmed the beneficial effect of N-acetylcysteine on
exacerbation rate. A further meta-analysis performed the
following year, focusing on the effect of mucolytics in
COPD and chronic bronchitis, including 12 studies with
NAC out of a total of 23, concluded that treatment with
these drugs is associated with a reduction of acute exacer-
bations and days of illnesses in these patients [88].
In a wide, multicentric trial [89] more than 5 hundred
COPD patients were randomized to receive NAC
600 mg/day or placebo for three years. The yearly rate of
decline in FEV1 was not decreased in patients given N-
acetylcysteine compared to those on placebo, as well as
the exacerbation rate, probably because a single dose of
600 mg is not sufficient to cause modifications of these
outcomes, even if the frequency of exacerbations was
significantly lower in COPD patients treated with NAC
and without inhaled corticosteroids. A similar finding
was evidenced by Sutherland et al. [90] in a meta-
analysis of 8 trials from which derived that NAC reduces
the risk of exacerbations in patients with COPD and this
effect can be attenuated by inhaled steroids but not by
smoking. This probably demonstrates that, besides the
adequate dosage and duration of NAC administration,
also a careful phenotyping of COPD patients is critical
for reaching the greatest benefit in terms of symptoms
control and exacerbation prevention. This is likely also
the reason why some studies performed in primary care
patients affected with COPD or chronic bronchitis did
not evidence any advantage from the administration of
NAC even for a long period but at a dose of 600 mg
daily [91].
On the contrary, Kasielsky and Novak [92] had previ-
ously demonstrated that 600 mg/day of NAC for
12 months are able to significantly decrease the hydro-
gen peroxide level in EBC of COPD patients compared
to placebo, but only after the sixth month of NAC
administration. On the same line, three years later De
Benedetto et al. [7] investigated the effect of NAC
1200 mg given for two months together with usual ther-
apy to stable patients affected with moderate COPD in
comparison to another group of patients given the usual
therapy only, and in both groups inhaled corticosteroids
(iCS) were suspended at the beginning of the trial. The
assay of H2O2 level in EBC was performed before the be-
ginning of NAC administration and at 15, 30 and 60 days
after the start of NAC therapy. As shown in Fig. 1, in pa-
tients treated with the usual therapy plus NAC signifi-
cantly lower concentrations of H2O2 were measured in
EBC at 15,30 and 60 days compared to the values re-
corded before the beginning of the treatment. The EBC
H2O2 values were instead increased at the same time
points compared to the basal value in COPD patients
treated with usual therapy only, likely due to a lack of
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control of airways chronic inflammation by iCS and in-
creased ROS production.
This study [7] also further points out that, in order to
efficiently counteract oxidative stress in COPD patients,
and decrease exacerbations rate and hospitalization [93],
higher NAC doses are needed than those used in past
investigations, generally limited to 600 mg once a day.
High-dose NAC supplementation in COPD patients
Based on the fact that lower NAC doses not always
yielded consistent and homogeneous results, and in
addition a dose-dependence of NAC was demonstrated
[69], several studies in last years focused on the
effectiveness of high-dose NAC (1200 mg/day) as add on
therapy to the usual one in COPD, especially with the
aim to decrease symptoms, prevent exacerbations, and
possibly improve their treatment.
For this purpose Zuin et al. [94] investigated the effi-
cacy and tolerability of high-dose NAC during the
course of an acute COPD exacerbation, in a double-
blind, double-dummy, placebo-controlled study includ-
ing 123 patients. Patients were randomly assigned to: a
group given NAC 1200 mg/day for 10 days in addition
to usual therapy (inhaled corticosteroids, theophylline,
anticholinergics and beta-2 adrenoceptor agonists); or a
group given NAC 600 mg/day for 10 days in addition to
usual therapy; or a group given placebo plus usual ther-
apy for 10 days. The anti-inflammatory effect was
assessed by the level of serum C-reactive protein (CRP)
and interleukin-8 (IL-8), while FEV1 and respiratory
symptoms score were also recorded. Patients were
examined at screening visit and at 5 and 10 days of
treatment. In patients with abnormal values of CRP, the
normalization of this index occurred in 90 % of patients
given NAC 1200 mg/day, in 52 % of those given
600 mg/day, and in 19 % of placebo patients. The differ-
ences of both NAC treatments were statistically signifi-
cant vs. placebo, but NAC 1200 was also significantly
different from NAC 600 (p = 0.002). Furthermore, serum
IL-8 was decreased at 10 days only after administration
of NAC 1200 mg/day, whereas FEV1 value showed small
but significant increase after both doses of NAC, so as
the symptoms improvement. NAC was well tolerated
also at the higher dose. The Authors concluded that a
daily dose of NAC 1200 mg improves the clinical out-
comes in patients with exacerbations of COPD.
An interesting, recent investigation [95] used new im-
aging tools to verify the effect of high-dose NAC in COPD
patients, finding a correlation between the image-based
improvement in respiratory function, mainly a better func-
tionality of small airways with consequent decrease in
lung hyperinflation, and effects of NAC supplementation
as witnessed by the glutathione increase.
The beneficial effects of high-dose NAC (1200 mg/day)
to prevent COPD exacerbations was investigated in 2013
in a systematic review and meta-analysis, based on 11
studies, performed by Shen et al. [96]. The high-dose of
NAC proved effective for the purpose of preventing exac-
erbations, whereas the lower dose demonstrated some
efficacy only in studies with high methodological quality.
In addition, both doses did not show any influence on
respiratory function.
A Chinese trial (HIACE) published the same year by
Tse et al. [97] confirmed the efficacy of high-dose NAC
against exacerbations in COPD patients, but revealed
also a beneficial effect on the small airways function, as
revealed by De Backer [95] with original imaging
techniques. The HIACE trial (The Effect of High Dose
N-acetylcysteine on Air Trapping and Airway Resistance
of Chronic Obstructive Pulmonary Disease—a Double-
blinded, Randomized, Placebo-controlled Trial) was
conducted in Hong-Kong on 120 patients randomly
assigned to take NAC 600 mg b.i.d. or placebo plus
usual therapy for one year. At the end of trial, the fre-
quency of COPD exacerbations with NAC was signifi-
cantly lower than with placebo, and the value of mean
forced expiratory flow (FEF25-75) was slightly but signifi-
cantly increased in NAC group compared to the placebo
one, so as the reactance and resistance obtained with
forced oscillation technique (FOT). Mean expiratory
flow on maximal flow-volume curve, long recognized as
a functional marker of small airways [98], has a great
variability and presents substantial interpretative prob-
lems [99–104], whereas low-frequency resistance and
reactance measured with the FOT would be more reli-
able to functionally explore the small airways [105–107].
The improvement of respiratory function with the long-
term administration of high-dose NAC (significant in-
crease in FOT reactance at 6 Hz and trend to decrease
Fig. 1 Mean values of H2O2 in expired breath condensate (EBC) of
COPD patients, treated with usual therapy plus NAC or with usual
therapy only, before the study and at 15, 30, and 60 days after the
start of the study. Mod from [7]
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of resistance at 6 Hz compared to placebo) is attributed
by Authors [97] to an effective antioxidant and anti-
inflammatory effect of the drug on small airways, and
consequently also on lung hyperinflation, as already
found [95, 108], due to the adequacy of dose and length
of therapy, differently from previous studies were the
dosage used was too low and/or the duration of therapy
was too short for the drug to be effective [63, 66, 92].
The improvement of respiratory function would be
another possible beneficial effect of high-dose NAC
that, while needing further confirmation in larger
studies, opens new and interesting perspectives for
the use of this drug in COPD treatment. More estab-
lished seems the effect of high-dose NAC as protect-
ive from COPD exacerbations, whose frequency in
this study was 0.96/year with NAC vs. 1.71/year with
placebo (p = 0.019), and this is possibly due, other
than to the antioxidant and antinflammatory effects,
also to the capacity of NAC to interfere with the bac-
terial functionality as demonstrated more in general
by mucolytic agents [97, 109]. Also a non-significant
trend towards a decreased rate of re-hospitalization
with NAC administration emerged from HIACE trial,
as already demonstrated in another study [93] and
this is important not only to prevent further progres-
sion of the disease, but also to contain the major
source of costs of COPD. Similarly important for its
practical implications appears also the demonstrated
capacity of NAC to increase the patient’s tolerability
to exercise, that is frequently reduced in COPD pa-
tients [110, 111]. No safety problems were recorded
also with this high dosage.
The following year the same group of investigators
made a post-hoc analysis [112] of their series focused on
the efficacy of NAC as protection from COPD exacerba-
tions according to the baseline patient’s exacerbation
risk as determined by GOLD criteria. Thus, patients
were divided in two groups, low and high risk of exacer-
bations, and in the high risk group NAC, compared to
placebo, was able to significantly increase the time to
first exacerbation, decrease the exacerbation frequency
and augment the probability of being exacerbation-free
at the end of one-year treatment (51.3 % of patients on
NAC vs. 24.4 % of patients on placebo; p = 0.013) (Fig. 2).
No significant benefit was achieved with NAC adminis-
tration in low risk group. The history of frequent exacer-
bations and the severity of COPD are important to
define a group of patients present in all severity stages of
GOLD classification [113] who present the greatest
functional decline, the major number of comorbidities
and are exposed to a poorer outcome and death [114].
Thus, the possibility of beneficially affecting the exacer-
bation frequency with high-dose NAC given for a long
period of time, in addition to other drugs that proven
useful for this purpose [115–118], appears an important
clue for the adequate treatment of COPD patients af-
fected with more severe disease, as already demonstrated
in other studies with high-dose mucolytics [119].(Fig. 3)
Indeed, in the same study, performed on Chinese
patients [112], authors themselves raise some doubts
about the generalization of their results to non-Chinese
white populations, but underline that NAC was effective
also in high-risk patients treated with inhaled corticoste-
roids, differently from previous findings [89].
Fig. 2 a Mean time to first exacerbation; b mean cumulative exacerbation frequency in Chinese COPD patients treated with high-dose NAC or
placebo in adjunct to usual therapy for one year and divided according to basal high or low exacerbation risk. Mod. from [111]
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This topic has been further investigated in another
wider Chinese study (the Placebo-controlled study on
efficAcy and safety of N-acetylcysTeine High dose in
Exacerbations of chronic Obstructive pulmoNary disease
[PANTHEON] study) [120], where high-dose NAC or
placebo were administered for one year, in addition to
existing individual therapy, to patients with stable,
moderate-to-severe COPD, and reporting at least 2 ex-
acerbation episodes during the last two years, stratified
by previous use of inhaled corticosteroids or not at the
beginning of the study. The primary outcome variable
was the rate of COPD exacerbations in one year, while
the secondary variables were the time to first exacerba-
tion, the amount of patients with severe exacerbations
(requiring systemic corticosteroids and antibiotics), and
the need for rescue bronchodilator therapy. One thou-
sand and six patients were randomly allocated to NAC
(504) or placebo (502), without between groups differ-
ences in baseline characteristics, and the duration of the
study was the same for both groups (319 days). At
the end of the study the number of exacerbations was
higher in placebo group (641 episodes) than in NAC
group (497 episodes), which corresponds to a mean
of 1.49 exacerbations/patient/year with placebo vs. 1.19
exacerbations/patient/year with NAC (p = 0.0011), with a
decrease in exacerbation risk of 22 % determined by NAC.
N-acetylcysteine induced a significantly lower frequency
of severe exacerbations and also decreased the duration of
the exacerbation compared to placebo as already found in
other studies [94], whereas previous ICS use did not seem
to influence the treatment effect, as already found in
another chinese trial [97, 112]. There was no differ-
ence in the time to first exacerbation between groups,
but it resulted reduced in patients with moderate disease
(GOLD II) treated with NAC, which also lengthened the
time to second and third exacerbation compared to pla-
cebo in the whole study group. NAC was well tolerated by
COPD patients also in this study.
The results of PANTHEON study are thus in accord-
ance with those of previous trials investigating the pre-
vention of exacerbations afforded by NAC [97, 119].
Authors of the PANTHEON trial also underline the
greater effect of NAC in patients with GOLD II disease,
thus suggesting that the antioxidant should be given at
an earlier stage of disease, to contrast the COPD pro-
gression towards more severe and irreversible alter-
ations, and for a long time in order to attain the greatest
efficacy from treatment. This draws further attention to
the necessity of knowing the type of COPD patients
where NAC can have the greatest effect [121].
The PANTHEON study raised some criticism [122],
firstly concerning the definition of exacerbation as used
in this trial. In fact, the occurrence of an exacerbation
was assessed based on daily symptoms recorded by pa-
tients, that is a quite easy but possibly deceptive method.
Besides, it was also noted that the phenotypes of patients
included in the study group could be different from
those of non-Chinese populations. The authors of the
PANTHEON trial rebutted that, even supposing an
under-reporting by patients, because of randomization
its proportion should be similar for both groups there-
fore without any influence on the observed differences.
On the other hand, mild exacerbations, that are recog-
nized to be the most conspicuous portion of total exac-
erbations [123], and in PANTHEON studies accounted
for 32 % of total, are only diagnosed by an increase in
habitual symptoms and generally do not require a more
intensive therapy or hospitalization.
In a comment on high-dose N-acetylcysteine in COPD
Cazzola and Matera [124] do not exclude the potential
Fig. 3 a Total number of COPD exacerbations occurred in one year in NAC group and in placebo group; b number of exacerbations/patient/year
in the two groups of patients. Mod from [119]
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usefulness of NAC for the treatment of COPD patients,
even if they rely more on the mucolytic properties of the
drug than on its antioxidant effect. Furthermore, these
authors once more point out the lack in PANTHEON
trial of a phenotypization of patients that likely would
have clarified the exact role of the antioxidant therapy in
COPD, as already demonstrated in the post-hoc analysis
of HIACE study where the efficacy against exacerbations
occurred only in the high-risk COPD patients, that is a
well defined group of patients where the disease has a
more severe connotation and poorer outcome.
However, in recently published evidence-based guide-
lines on the prevention of acute exacerbations of COPD
by American College of Chest Physicians and Canadian
Thoracic Society, N-acetylcysteine therapy is also recom-
mended (grade 2B) for patients with moderate to severe
COPD and a history of two or more exacerbations in the
previous 2 years [125]. This evidence is also present in
the GOLD recommendations [2].
Conclusions
The title of this review puts some questions about add-
ing N-acetylcysteine to the treatments of COPD.
The first question is why N-acetylcysteine should be
added to other drugs routinely used at present in patients
with COPD. The antioxidant and anti-inflammatory prop-
erties of NAC are based on a consistent amount of proofs
obtained in vitro and in vivo and new information is con-
tinuously yielded about the useful involvement of this
drug into the most intimate mechanisms playing a de-
cisive role in triggering and maintaining respiratory in-
flammation. The inflammatory nature of COPD has
already been well demonstrated [126], so as that oxidative
stress has a close inter-relationship with the inflammatory
process [5, 11, 20, 21, 33]. Moreover, the ROS level in the
lung is steadily increased in COPD patients [10, 83]. NAC
has the potential to interfere with the processes that
underline COPD pathogenesis and, as a matter of fact, the
respiratory level of oxidants is decreased after its adminis-
tration [7]. Thus, the antioxidant and mucolytics proper-
ties of NAC have the potential for being a useful adjunct
in COPD therapy [57, 69]. Even because a recent investi-
gation has demonstrated that NAC is also able to enhance
the effectiveness of antimuscarinic bronchodilators gener-
ally used in COPD patients [127].
The second question, that is how to administer N-
acetylcysteine, seems just an overcome issue, because
the numerous trials that have investigated NAC demon-
strated that oral route is efficient, simply to use, and well
tolerated, without excluding however other potential
modalities of administration. The daily dosage of the
drug raised some perplexities in the past, but it is well
established by now that to achieve some benefit in terms
of prevention from COPD exacerbations or possibly of
respiratory function and symptoms improvement, high-
dose NAC (1200 mg/day on average) must be adminis-
tered for a long period of time. All the most recent trials
used this dosage for one year to evaluate the effect of
NAC in adjunct to usual therapy in comparison to
placebo.
Finally, the most critical point, still matter of discus-
sion, is when and to which COPD patients NAC therapy
should be addressed. The results of widely sized studies
performed to assess the value of high-dose adjunct of
NAC or other mucolytic agents to COPD therapy are
encouraging, but they were obtained in Chinese patients
[97, 119, 120] and the limits to apply these results are
above underlined. However, these studies also evidenced
important and seemingly conflicting results, because one
revealed that high-dose NAC reaches its greatest efficacy
in patients characterized by a high risk of being exacer-
bated, whereas the other one revealed more NAC effi-
cacy in those patients who still are in a phase of
moderate gravity of the disease. Likely, this discrepancy
in results may depend on the composition of the en-
rolled patients in these studies, and they can clearly con-
vey the need for a better phenotyping of COPD patients
to investigate, as already come out for other respiratory
drugs like bronchodilators and inhaled corticosteroids.
Furthermore, these results could assign to NAC a
broader role than previously recognized, that is that of a
drug able to be used as add on therapy to decrease the
exacerbation rate and symptoms score, represented by
cough and phlegm, in COPD patients, also without the
moderate to severe airways obstruction.
In spite of the above mentioned limits, the results of
past and recent studies can offer very important per-
spectives for the use of oral NAC as a valid add on ther-
apy in chronic bronchitis and COPD and other widely
sized clinical trials in different populations are hoped for
in order to establish the role of high-dose NAC in the
therapy of COPD patients.
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